RiverStone Health says local vaccination rates have stayed steady and are seeing the usual rush of kids coming in for their annual back-to-school shots.

At first glance, Pfizer delivered a strong Q2 and upped its 2025 full-year EPS guidance. Click here to find out why I rate ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

Trump Media shares dipped after launching its AI-powered Truth Search beta with Perplexity, even as the company reported $3.1 ...

Leading the charge this morning is Smith & Nephew PLC (LSE:SN), up over 11% after the knee- and hip-replacement group ...

Amgen beat Q2 earnings and revenue expectations, raised 2025 guidance, and reported strong product sales growth across key ...

PFIZER said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting higher-than-expected second-quarter earnings on Tuesday.

On the company’s Q2 earning call, Pfizer (PFE) noted that the company’s guidance “absorbs the impact of the currently imposed ...

Research and development expenses fell 48.2% compared to Q2 2024, while general and administrative costs rose 121.1%, Research and development expenses were $1.0 million compared to $2.1 million for ...

In a report released today, Steve Scala from TD Cowen maintained a Hold rating on Pfizer, with a price target of $30.00. The company’s shares closed yesterday at $23.53. Take advantage of TipRanks ...

Viatris (VTRS) is set to announce Q2 earnings amid EPS and revenue declines. Learn about its recent trials, stock dip, and Wall Street's Hold rating.

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...